引用本文:宁 琳,韦良宏,陈海东,韦良鹏,谭宗连,劳雪莲.血清胃蛋白酶原指导质子泵抑制剂在功能性消化不良中的应用价值[J].中国临床新医学,2019,12(11):1199-1202.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 27次   下载 25 本文二维码信息
码上扫一扫!
分享到: 微信 更多
血清胃蛋白酶原指导质子泵抑制剂在功能性消化不良中的应用价值
宁 琳,韦良宏,陈海东,韦良鹏,谭宗连,劳雪莲
535001 广西,钦州市第一人民医院消化内科
摘要:
[摘要] 目的 探讨血清胃蛋白酶原(pepsinogen,PG)在预测功能性消化不良(functional dyspepsia,FD)患者中使用质子泵抑制剂(proton pump inhibitors,PPIs)疗效的可行性。方法 选择该院2016-03~2019-03诊断为FD的患者100例。所有患者均接受雷贝拉唑治疗(1次/d,20 mg/次),在接受治疗前均抽取血清进行PGⅠ、PGⅡ检测。治疗4周后以症状评分量表(GSRS)对研究对象进行症状评分,根据评分将研究对象分为有效组(54例)和无效组(46例),比较两组治疗前的PGⅠ、PGⅡ、PGⅠ/PGⅡ比值(PGR)水平。PGⅠ、PGⅡ、PGR与PPIs疗效相关性分析采用Spearman秩相关分析。结果 有效组治疗前的血清PGⅠ、PGR水平高于无效组,差异有统计学意义(P<0.05);PGⅡ水平低于无效组,差异无统计学意义(P>0.05);无效组治疗前的血清PGR异常检出率高于有效组,差异有统计学意义(P<0.05)。Spearman秩相关分析结果显示,PGⅠ、PGR与治疗后症状积分降低值呈正相关(P<0.05)。结论 FD患者治疗前的PG水平对预测PPIs治疗FD患者的疗效具有临床指导价值。
关键词:  血清胃蛋白酶原  功能性消化不良  质子泵抑制剂  疗效
DOI:10.3969/j.issn.1674-3806.2019.11.13
分类号:R 573.9
基金项目:广西卫健委科研课题(编号:Z2016074)
The application value of serum pepsinogen guiding proton pump inhibitors in treatment of functional dyspepsia
NING Lin, WEI Liang-hong, CHEN Hai-dong, et al.
Department of Digestive Medicine, the First People′s Hospital of Qinzhou City, Guangxi 535001, China
Abstract:
[Abstract] Objective To explore the feasibility of serum pepsinogen(PG) in predicting the efficacy of proton pump inhibitors(PPIs) in patients with functional dyspepsia(FD). Methods One hundred patients with FD were selected in our hospital from March 2016 to March 2019. All the patients were treated with rabeprazole(20 mg, qd), and before the treatment, the serum of all the patients was taken for prostaglandin Ⅰ(PGⅠ) and prostaglandin Ⅱ(PGⅡ) detections. After 4 weeks of treatment, the research subjects were divided into the effective group(n=54) and the ineffective group(n=46) according to the Gastrointestinal Symptom Rating Scale(GSRS). The levels of PGⅠ, PGⅡ and PGR(PGⅠ/PGⅡ) were compared between the two groups before treatment. Spearman rank correlation analysis was used to analyze the correlations of PGⅠ, PGⅡand PGR with the therapeutic effect of PPIs. Results The levels of serum PGⅠ and PGR in the effective group were significantly higher than those in the ineffective group before treatment(P<0.05). The level of PGⅡ in the effective group was lower than that in the ineffective group, but with no significant difference(P>0.05). The abnormal rate of serum PGR in the ineffective group was significantly higher than that in the effective group before treatment(P<0.05). The results of Spearman rank correlation analysis showed that PGⅠ and PGR were positively correlated with the reduction of symptoms scores after treatment(P<0.05). Conclusion The PG level of FD patients before treatment has clinical guiding value in predicting the efficacy of PPIs in FD patients.
Key words:  Serum pepsinogen  Functional dyspepsia(FD)  Proton pump inhibitors(PPIs)  Therapeutic effect